Clinical Trial: Phase 3 study to evaluate IOP lowering therapy in open angle glaucoma and ocular hypertension C-02-41


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

Phase 3 study to evaluate IOP lowering therapy in open angle glaucoma and ocular hypertension C-02-41

This study is currently recruiting patients.

Sponsored by:	Alcon Research
Information provided by:	Alcon Research

Purpose

To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.

Condition	Treatment or Intervention	Phase
Open-Angle Glaucoma Ocular Hypertension	Drug: Alcon Investigational Agent	Phase III

MedlinePlus related topics: Eye Diseases; Glaucoma

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title: Phase III safety and efficacy study to evaluate combination IOP lowering therapy in open angle glaucoma and ocular hypertensive patients (C-02-41).

Eligibility

Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both

Criteria

Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension; visual acuity of 20/80 to 20/400 or better (Snellen equivalent) or logMAR visual acuity not worse than 0.6. Clinically relevant ophthalmic or systemic conditions may be excluded.

Location and Contact Information

Alcon Call Center 1-888-451-EYES (3937) alconlabs.com

Clinical Trial Sites, Multiple Locations Throughout the United States, ; Recruiting

More Information

Study ID Numbers: C-02-41; C-02-41
Record last reviewed: October 2002
Record first received: October 8, 2002
ClinicalTrials.gov Identifier: NCT00047528
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-10

U.S. National Library of Medicine, Contact NLM Customer Service

National Institutes of Health, Department of Health & Human Services